 TNF inhibitors are commonly used to treat psoriasis and are considered first-line options in certain settings. Several biosimilar drugs based on anti-TNF agents such as adalomumab, infliximab, and etinosept are now available for use in patients with psoriasis. The favorable cost differential of biosimilars is expected to improve access to biologic therapy for biologic naive psoriasis patients and substantial cost savings can be made if patients are switched to biosimilars. Although most clinical testing of anti-TNF biosimilars approved for use in psoriasis has been performed in patients with rheumatoid arthritis, the process of extrapolation is tightly regulated and scientifically justified. The available real world evidence of the safety and efficacy of anti-TNF agents in patients with psoriasis complements clinical trial data in patients with rheumatoid arthritis and clinicians should have confidence to use biosimilars for the treatment of psoriasis when equipped with the appropriate knowledge. This article was authored by Jonathan Barker, Gian Piero Girolamoni, Alexander Etchberg, and others. We are article.tv, links in the description below.